Chime Biologics (Wuhan) Co., Ltd, contract development and manufacturing organisation, has completed over $190 million in its Series A+ round of financing led by Hong Kong’s alternative asset management player VMS Group.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
